Latest News

Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount ...

Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and E

Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate...

Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and

Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,00...

Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000

California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Stateme...

California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements A

New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Ti...

New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to

Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes

Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes

Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024

Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024

Teva Reports Third Quarter 2021 Financial Results

Teva Reports Third Quarter 2021 Financial Results

Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate

Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate

Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021

Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live w...

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with R

‘Medicine Miles’ Becoming a Concern for European Patients

‘Medicine Miles’ Becoming a Concern for European Patients

Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October...

Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27,

Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare...

Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disp

Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhal...

Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Us

Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims

Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congre...

Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 20

Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatme...

Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment fo

Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be ...

Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be prese

Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazi...

Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) T

Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion A...

Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across

Teva Reports Second Quarter 2021 Financial Results

Teva Reports Second Quarter 2021 Financial Results

Teva Announces Changes to Executive Management Team

Teva Announces Changes to Executive Management Team

Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 2...

Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 20

Teva and Bioeq Announce Commercial Partnership for Biosimilar

Teva and Bioeq Announce Commercial Partnership for Biosimilar

Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Ja...

Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan f

Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution...

Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live w...

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with R

New Data Supporting the Safety and Efficacy Profile of AJOVY® (fremanezumab) Shared at 7th European ...

New Data Supporting the Safety and Efficacy Profile of AJOVY® (fremanezumab) Shared at 7th European Acade

Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Facto...

Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors Ma

Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once ...

Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Present...

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache So...

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society

Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets

Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets

Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society Internatio...

Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International C

Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of...

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bact

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Assoc...

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Associatio

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the...

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Trea

Teva Reports First Quarter 2021 Financial Results

Teva Reports First Quarter 2021 Financial Results

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia ...

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clini

Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults w...

Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with A

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Red...

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reductio

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine)...

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tabl

Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 2...

Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 28, 20

Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, us...

Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to

Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal...

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring

Teva Sets Ambitious Long-Term Environmental Goals As Part of Renewed ESG Strategy

Teva Sets Ambitious Long-Term Environmental Goals As Part of Renewed ESG Strategy